test

Craig Skaling

@Tcg Crossover Management, Llc

Latest period2024 - Q3ReportedManaged Assets$1.18BTotal holdings36
Assets growth rate23.02%Assets growth rate (2-Q avg)-0.56%Continuous growth in asset value1 quarters

Portfolio positions

This chart displays the top 10 holdings in Tcg Crossover Management, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 36 positions.

Assets under management

The assets under management (AUM) of Tcg Crossover Management, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.18B in assets, with a quarterly growth rate of 23.02% and a 2-quarter average growth rate of -0.56%. The portfolio is managed by Craig Skaling, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
IRONDisc Medicine, Inc.
Recent Activity
2.03%
$23.929M
486,957 shares@ $49.15 avg price
FULCFulcrum Therapeutics Inc
Recent Activity
New Position
1.59%
$18.742M
5.25M shares@ $3.57 avg price
MBXMbx Biosciences Inc
Recent Activity
New Position
1.44%
$16.887M
650,000 shares@ $25.98 avg price
AMLXAmylyx Pharmaceuticals Inc
Recent Activity
New Position
1.28%
$15.046M
4.644M shares@ $3.25 avg price
ADVMAdverum Biotechnologies, Inc.
Recent Activity
New Position
1.2%
$14.099M
2.008M shares@ $7.03 avg price
TRDAEntrada Therapeutics Inc
Recent Activity
0.8%
$9.348M
584,955 shares@ $15.99 avg price
VTGNVistagen Therapeutics Inc
Recent Activity
New Position
0.69%
$8.057M
2.677M shares@ $3.01 avg price
TARSTarsus Pharmaceuticals, Inc.
Recent Activity
Decreased -58.32%
0.65%
$7.625M
231,820 shares@ $32.9 avg price
EYPTEyepoint Pharmaceuticals, Inc.
Recent Activity
0.63%
$7.369M
922,335 shares@ $8.0 avg price
NKTRNektar Therapeutics
Recent Activity
0.45%
$5.2M
4M shares@ $1.3 avg price